ROIV

Roivant Sciences Ltd
$36.13+$0.24+0.67%Price as of Nov 3, 2026, 9:33 AM ET

Key stats

Market cap
26.1B
Open
—
Day range
—
52-week range
$19.32 – $42.50
Volume
74.8K
Avg volume
6.63M

Earnings

Q1 FY27
Actual$-0.26
Q4 FY26
Actual$0.42
Q3 FY26
Actual$-0.38
Q2 FY26
Actual$-0.17

Next earnings call Nov 9, 2026

About

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Employees
721
Headquarters
London,